Listing of Claims:

In the Claims:

Claims 1-51 (Canceled)

52. (Currently amended) A method of inhibiting the MARCKS protein-related release of an inflammatory mediator in a subject comprising:

administering to a subject suffering from inflammation a therapeutically effective amount of a pharmaceutical composition comprising a MANS peptide consisting of an amino acid sequence of SEQ ID NO:1, in an amount effective to block the MARCKS protein-related release of mediators of inflammation secreted from infiltrating inflammatory cells at a site of inflammation in the subject.

53. (Currently amended) The method according to claim 52, wherein said ~~inflammatory mediator results in~~ inflammation is caused by a respiratory disease ~~diseases~~.

54. (Currently amended) The method according to claim 52 ~~53~~, wherein said ~~respiratory diseases are selected from the group consisting of~~ inflammation is caused by asthma~~, chronic bronchitis, and COPD~~.

55. – 56. (Canceled)

57. (Previously presented) The method according to claim 52, wherein said subject is a mammal.

58. (Previously presented) The method according to claim 57, wherein said mammal is selected from the group consisting of humans, canines, equines and felines.

59. (Previously presented) The method according to claim 52, wherein said administering step is selected from the group consisting of topical administration, parenteral administration, rectal administration, pulmonary administration, nasal administration, inhalation and oral administration.

60. (Previously presented) The method according to claim 59, wherein said pulmonary administration is selected from the group consisting of aerosol, dry powder inhaler, metered dose inhaler, and nebulizer.

61. (Currently amended) The method according to claim 52, wherein said inflammatory mediators are ~~produced~~ released by cells selected from the group consisting of neutrophils, basophils, eosinophils, monocytes and leukocytes.

62. (Currently amended) The method according to claim 52, wherein the therapeutically effective amount of a MANS peptide is administered orally, parenterally, ~~cavitarily,~~ rectally, nasally or through an air passage.

63. (Previously presented) The method according to claim 52, further comprising administering to said subject a second molecule selected from the group consisting of an antibiotic, an antiviral compound, an antiparasitic compound, an anti-inflammatory compound, and an immumosuppressant.

64. (Currently amended) A method of inhibiting the MARCKS protein-related release of an inflammatory mediator from ~~a membrane-bound vesicle in~~ an infiltrating inflammatory cell in a subject suffering from inflammation caused by a disease or condition involving inflammation comprising:

administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a MANS peptide consisting of an amino acid sequence of SEQ ID NO:1 in an amount effective to inhibit said MARCKS protein-related release of said inflammatory mediator from ~~said vesicle in~~ said infiltrating inflammatory cell in the subject.

65. (Currently amended) The method according to claim 64, wherein said inhibiting the MARCKS protein-related release of an inflammatory mediator comprises blocking or reducing the MARCKS protein-related release of an inflammatory mediator from ~~said vesicle in~~ said infiltrating inflammatory cell.

66. (Currently amended) The method according to claim 64, wherein said inflammation is caused by a respiratory disease ~~diseases~~.

67. (Currently amended) The method according to claim ~~66~~ 64, wherein said ~~respiratory diseases are selected from the group consisting of~~ said inflammation is caused by asthma~~, chronic bronchitis, and COPD~~.

68. - 69. (Canceled)

70. (Currently amended) The method according to claim 64, wherein said inflammatory ~~cells are cells~~ cell is selected from the group consisting of neutrophils, basophils, eosinophils, monocytes, leukocytes and a combination thereof.

71. (Previously presented) The method according to claim 64, wherein said subject is a mammal.

72. (Previously presented) The method according to claim 71, wherein said mammal is selected from the group consisting of humans, canines, equines and felines.

73. (Previously presented) The method according to claim 64, wherein said administering step is selected from the group consisting of topical administration, parenteral administration, rectal administration, pulmonary administration, nasal administration, inhalation and oral administration.

74. (Previously presented) The method according to claim 73, wherein said pulmonary administration is selected from the group of aerosol, dry powder inhaler, metered dose inhaler, and nebulizer.

75. (Previously presented) The method according to claim 64, further comprising administering to said subject a second molecule selected from the group consisting of an

antibiotic, an antiviral compound, an antiparasitic compound, an anti-inflammatory compound, and an immumosuppressant.

76. – 84. (Canceled)

85. (New) The method according to claim 52, wherein said inflammation is caused by chronic bronchitis.

86. (New) The method according to claim 52, wherein said inflammation is caused by chronic obstructive pulmonary disease (COPD).

87. (New) The method according to claim 52, wherein said inflammation is caused by cystic fibrosis.

88. (New) The method according to claim 64, wherein said inflammation is caused by chronic bronchitis.

89. (New) The method according to claim 64, wherein said inflammation is caused by chronic obstructive pulmonary disease (COPD).

90. (New) The method according to claim 64, wherein said inflammation is caused by cystic fibrosis.

91. (New) The method according to claim 64, wherein the therapeutically effective amount of a MANS peptide is administered orally, parenterally, rectally, nasally or through an air passage.